These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 7866090)

  • 1. ABC of breast diseases. Role of systemic treatment for primary operable breast cancer.
    Richards MA; Smith IE; Dixon JM
    BMJ; 1994 Nov; 309(6965):1363-6. PubMed ID: 7866090
    [No Abstract]   [Full Text] [Related]  

  • 2. Adjuvant therapy in breast cancer.
    Robert NJ
    Obstet Gynecol Clin North Am; 1994 Dec; 21(4):693-707. PubMed ID: 7731642
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of tamoxifen as the primary treatment of operable breast cancer in the high risk patient.
    Falk GL; Gwynne-Jones D; Gray JG
    Aust N Z J Surg; 1989 Jul; 59(7):543-5. PubMed ID: 2751544
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Adjuvant therapies in breast carcinoma].
    Joss R; Brunner K
    Schweiz Rundsch Med Prax; 1991 Mar; 80(11):247-54. PubMed ID: 2024099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Systemic adjuvant therapy of breast cancer: myths and controversies].
    Roy JA; Piccart MJ
    Rev Med Brux; 1996 Sep; 17(4):267-70. PubMed ID: 8927859
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Late effects of adjuvant therapy for breast cancer.
    Shapiro CL; Recht A
    J Natl Cancer Inst Monogr; 1994; (16):101-12. PubMed ID: 7999452
    [No Abstract]   [Full Text] [Related]  

  • 7. Comparison of mastectomy with tamoxifen for treating elderly patients with operable breast cancer.
    Robertson JF; Todd JH; Ellis IO; Elston CW; Blamey RW
    BMJ; 1988 Aug 20-27; 297(6647):511-4. PubMed ID: 3139179
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer.
    Gasparini G; Barbareschi M; Doglioni C; Palma PD; Mauri FA; Boracchi P; Bevilacqua P; Caffo O; Morelli L; Verderio P
    Clin Cancer Res; 1995 Feb; 1(2):189-98. PubMed ID: 9815973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Postoperative adjuvant chemotherapy followed by adjuvant tamoxifen versus nil for patients with operable breast cancer: a randomised phase III trial of the European Organisation for Research and Treatment of Cancer Breast Group.
    Morales L; Canney P; Dyczka J; Rutgers E; Coleman R; Cufer T; Welnicka-Jaskiewicz M; Nortier J; Bogaerts J; Therasse P; Paridaens R; ;
    Eur J Cancer; 2007 Jan; 43(2):331-40. PubMed ID: 17134892
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [What is the benefit of adjuvant therapy in breast cancer?].
    Sauer H
    Fortschr Med; 1992 Nov; 110(30):16-8, 20. PubMed ID: 1468737
    [No Abstract]   [Full Text] [Related]  

  • 11. Adjuvant treatment of breast cancer.
    Akerley WL
    R I Med; 1995 Sep; 78(9):250-3. PubMed ID: 7579720
    [No Abstract]   [Full Text] [Related]  

  • 12. Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer.
    Powles TJ; Hickish TF; Makris A; Ashley SE; O'Brien ME; Tidy VA; Casey S; Nash AG; Sacks N; Cosgrove D
    J Clin Oncol; 1995 Mar; 13(3):547-52. PubMed ID: 7884414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant tamoxifen-induced mammographic breast density reduction as a predictor for recurrence in estrogen receptor-positive premenopausal breast cancer patients.
    Ko KL; Shin IS; You JY; Jung SY; Ro J; Lee ES
    Breast Cancer Res Treat; 2013 Dec; 142(3):559-67. PubMed ID: 24233999
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Carcinoma of the breast.
    Allum WH; Smith IE
    Br J Hosp Med; 1995 Sep 20-Oct 3; 54(6):255-8. PubMed ID: 8542173
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Adjuvant hormonal therapy in lymph node-negative breast carcinoma patients in the postmenopause].
    Kurz C; Scholten C; Zielinski C; Czerwenka K; Kubista E; Spona J; Sevelda P
    Dtsch Med Wochenschr; 1992 Dec; 117(51-52):1943-6. PubMed ID: 1478168
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Co-expression of estrogen receptor alpha and Apolipoprotein D in node positive operable breast cancer--possible relevance for survival and effects of adjuvant tamoxifen in postmenopausal patients.
    Søiland H; Skaland I; Varhaug JE; Kørner H; Janssen EA; Gudlaugsson E; Baak JP; Søreide JA
    Acta Oncol; 2009; 48(4):514-21. PubMed ID: 19107621
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic adjuvant therapy for breast cancer.
    Reed EC
    Nebr Med J; 1996 Mar; 81(3):48-50. PubMed ID: 8907820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Adjuvant systemic therapy in breast carcinoma in the 1990s: status of things and open questions].
    Goldhirsch A; Neuenschwander H; Castiglione M; Senn HJ; Cavalli F
    Schweiz Med Wochenschr; 1990 Nov; 120(47):1771-83. PubMed ID: 2255883
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of prostate-specific antigen (PSA) correlates with poor response to tamoxifen therapy in recurrent breast cancer.
    Foekens JA; Diamandis EP; Yu H; Look MP; Meijer-van Gelder ME; van Putten WL; Klijn JG
    Br J Cancer; 1999 Feb; 79(5-6):888-94. PubMed ID: 10070886
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Sequencing of adjuvant treatment after surgery for invasive breast cancer].
    Petit T; Claude L; Carrie C
    Cancer Radiother; 2004 Feb; 8(1):54-8. PubMed ID: 15093202
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.